Stock ENTO ENTERO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.7 USD +2.66% Intraday chart for Entero Therapeutics, Inc. +5.06% -35.71%
May. 20 Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index CI
May. 17 First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index
First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc
First Wave BioPharma Changes Name to Entero Therapeutics
First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index
First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
First Wave BioPharma, Inc. announced a financing transaction
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Sector Update: Health Care Stocks Retreating Late Afternoon
Sector Update: Health Care
First Wave BioPharma Shares Fall After Acquiring ImmunogenX
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data
First Wave Biopharma, Inc. Announces Management Changes
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTO Stock
  4. News Entero Therapeutics, Inc.
  5. Other languages